Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma

J Thorac Oncol. 2022 Jan;17(1):30-33. doi: 10.1016/j.jtho.2021.07.029.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Humans
  • Ipilimumab / therapeutic use
  • Lung Neoplasms* / drug therapy
  • Mesothelioma, Malignant*
  • Nivolumab / therapeutic use
  • Standard of Care

Substances

  • Ipilimumab
  • Nivolumab